These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9614724)

  • 61. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal.
    Durelli L; Bongioanni MR; Ferrero B; Oggero A; Marzano A; Rizzetto M
    Neurology; 1998 Feb; 50(2):570-1. PubMed ID: 9484407
    [No Abstract]   [Full Text] [Related]  

  • 62. Why interferon beta 1b was licensed is a mystery.
    Harvey P
    BMJ; 1996 Aug; 313(7052):297-8. PubMed ID: 8704553
    [No Abstract]   [Full Text] [Related]  

  • 63. Therapeutic developments in multiple sclerosis.
    Goodin DS
    Expert Opin Investig Drugs; 2000 Apr; 9(4):655-70. PubMed ID: 11060700
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Betaseron advisory.
    Panitch HS
    Neurology; 1995 Jul; 45(7):1428-9. PubMed ID: 7617216
    [No Abstract]   [Full Text] [Related]  

  • 65. [Interferon beta 1-a in multiple sclerosis: 1-year experience in 62 patients].
    Tilbery CP; Felipe E; Moreira MA; Mendes MF; França AS
    Arq Neuropsiquiatr; 2000 Jun; 58(2B):452-9. PubMed ID: 10920406
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 67. [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].
    Huber S; Spycher M; Lechner-Scott J; Bellaiche Y; Steck AJ; Kappos L
    Schweiz Med Wochenschr; 1996 Aug; 126(35):1475-81. PubMed ID: 8927950
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Does interferon beta help in secondary progressive MS?
    Cohen JA; Antel JP
    Neurology; 2004 Nov; 63(10):1768-9. PubMed ID: 15557486
    [No Abstract]   [Full Text] [Related]  

  • 70. Interferon beta-1a in primary progressive multiple sclerosis.
    Leary SM; Thompson AJ
    J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New treatments for multiple sclerosis.
    Hutchinson M
    Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
    [No Abstract]   [Full Text] [Related]  

  • 72. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.
    Kendrick M; Johnson KI
    Pharmacoeconomics; 2000 Jul; 18(1):45-53. PubMed ID: 11010603
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Interferon β].
    Matsushita T
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():196-204. PubMed ID: 26480700
    [No Abstract]   [Full Text] [Related]  

  • 74. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
    Li DK; Paty DW
    Ann Neurol; 1999 Aug; 46(2):197-206. PubMed ID: 10443885
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon treatment for multiple sclerosis patients in Hong Kong.
    Lau KK; Lee PO; Chan KY; Chan YW; Chin KF
    Hong Kong Med J; 2000 Jun; 6(2):221-3. PubMed ID: 10895148
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interferon beta in multiple sclerosis.
    Napier JC
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465197
    [No Abstract]   [Full Text] [Related]  

  • 78. Interferon beta-1a treatment and African Americans.
    Cantor FK
    Arch Neurol; 2006 Apr; 63(4):627-8; author reply 628. PubMed ID: 16606785
    [No Abstract]   [Full Text] [Related]  

  • 79. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.